Abstract:The recently discovered long noncoding RNAs have the potential to regulate many biological processes, which are aberrantly expressed in many tumor types. Our previous study showed that the long noncoding RNA-growth arrest-specific transcript 5 (GAS5) was decreased in lung cancer tissue, which contributed to the proliferation and apoptosis of nonsmall cell lung cancer (NSCLC). GAS5 was also associated with the prognosis of lung cancer patients. These results suggest that GAS5 may represent a novel prognostic indicator and a target for gene therapy in NSCLC. However, the expression and diagnosis significance of GAS5 in the plasma of NSCLC patients was unknown. The plasma samples were more readily available than the tissue samples in clinical, so we designed the study to investigate the diagnosis value of GAS5 in blood samples. In our study, 90 patients with NSCLC and 33 healthy controls were included. Blood samples were collected before surgery and therapy. We extracted the free RNA in the plasma and analyzed the expression of GAS5 with quantitative reverse transcription PCR. Suitable statistics methods were used to compare the plasma GAS5 levels of preoperative and postoperative plasma samples between the NSCLC patients and healthy controls. Receiver-operating characteristic curve analysis was used to evaluate the diagnostic sensitivity and specificity of plasma GAS5 in NSCLC. The results showed that GAS5 was detectable and stable in the plasma of NSCLC patients. Furthermore, the plasma levels of GAS5 were significantly down-regulated in NSCLC patients compared with healthy controls (P=0.000). Moreover, GAS5 levels increased markedly on the seventh day after surgery compared with preoperative GAS5 levels in NSCLC patients (P=0.003). GAS5 expression levels could be used to distinguish NSCLC patients from control patients with an area under the curve of 0.832 (P<0.0001; sensitivity, 82.2%; specificity, 72.7%). The combination of the GAS5 and carcinoembryonic antigen could produce an area of 0.909 under the receiver-operating characteristic curve in distinguishing NSCLC patients from control subjects (95% confidence interval 0.857-0.962, P=0.000). We have demonstrated that GAS5 expression was decreased in NSCLC Plasma. Plasma samples were more accessible than tissue samples in clinical; therefore, GAS5 could be an ideal biomarker for the diagnosis of NSCLC.

Circulating Long Noncoding RNA GAS5 As a Novel Biomarker for Patients with Atrial Fibrillation

Retard or Exacerbate: Role of Long Non-Coding RNA Growth Arrest-Specific 5 in the Fibrosis

Long noncoding RNA GAS8-AS1: A novel biomarker in human diseases

Circulating Long Non-Coding RNA GAS5 Is a Novel Biomarkers for the Diagnosis of Non-Small Cell Lung Cancer

Identification Of Circulating Long Non-Coding Rna Gas5 As A Potential Biomarker For Non-Small Cell Lung Cancer Diagnosis

P6597Long-term Impact of Catheter Ablation on Growth Differentiation Factor-15 and Neutrophil-Lymphocyte Ratio in Paroxysmal Atrial Fibrillation

Expression of the Long Noncoding RNA GAS5 Correlates with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease

Circulating long noncoding RNA GAS5 as a potential biomarker in breast cancer for assessing the surgical effects

Functional Analysis of Serum Long Noncoding RNAs in Patients with Atrial Fibrillation

Systematic Review and Meta-Analysis of the Utility of Long Non-Coding RNA GAS5 As a Diagnostic and Prognostic Cancer Biomarker.

Correlation between circulating long non-coding RNA growth arrest-specific transcript 5 and coronary artery calcification

A Critical Role for the Long Non‐coding RNA GAS5 in Proliferation and Apoptosis in Non‐small‐cell Lung Cancer

Identification of long non-coding RNAs as novel biomarker and potential therapeutic target for atrial fibrillation in old adults.

Role of circulating long non-coding RNA for the improvement of the predictive ability of the CHA 2 DS 2 -VASc score in patients with atrial fibrillation

Identification of Atrial Fibrillation-Related lncRNA Based on Bioinformatic Analysis

Genome-wide Profiling Reveals Atrial Fibrillation-Related Circular RNAs in Atrial Appendages

Genome-wide screening of functional long noncoding RNAs in the epicardial adipose tissues of atrial fibrillation

Left Atrial Appendage Circular RNAs Are New Predictors of Atrial Fibrillation Recurrence after Surgical Ablation in Valvular Atrial Fibrillation Patients

Soluble PILRα: A Novel Plasma Biomarker for Atrial Fibrillation Progression and Recurrence after Catheter Ablation

Tumor‐derived exosomal lncRNA GAS5 as a biomarker for early‐stage non‐small‐cell lung cancer diagnosis